Drug Trial Radar · NCT06671054
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Oct 1, 2024
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- SynAct Pharma ApsIndustry
- Sponsor type
- Industry
- Collaborators
- NBCD A/S
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
Conditions
- Rheumatoid Arthritis (RA)
Interventions
AP1189, 40 mgDrug
AP1189 tablets for oral use
AP1189, 70 mgDrug
AP1189 tablets for oral use
AP1189, 100 mgDrug
AP1189 tablets for oral use
AP1189 matching placeboDrug
AP1189 tablets for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Disease Activity Score 28 (DAS28)-C-Reactive Protein (CRP)Time frame: Week 12
Locations
11 sites in 5 countries. Site status is shown where the registry gives one.
Nouvelle Clinical Research LLC
Cutler Bay, Florida · Recruiting
Millennium Medical Research LLC
Miami, Florida · Recruiting
Altoona Center for Clinical Research
Duncansville, Pennsylvania · Recruiting
Diagnostic Consultative Center Aleksandrovska
Sofia, Bulgaria · Recruiting
Medical Center Tera Medico
Vratsa, Bulgaria · Recruiting
Sanos Clinic Herlev
Herlev, Denmark · Recruiting
IMSP Spitalul Clinic Municipal "Sfanta Treime"
Chisinau, Moldova · Recruiting
M2Mmed
Chorzów, Poland · Recruiting
Vita Longa Sp. z o. o.
Katowice, Poland · Recruiting
Medyczne Centrum Hetmańska
Poznan, Poland · Recruiting
DC-MED Michal Kowalski S.K.
Swidnica, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.